These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7249126)

  • 41. [Economic assessment of Caelyx versus topotecan in advanced ovarian cancer].
    Girre V; Pujade-Lauraine E; Durand-Zaleski I
    Bull Cancer; 2003 Nov; 90(11):983-8. PubMed ID: 14706902
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The economic impact of chronic fatigue syndrome.
    Lloyd AR; Pender H
    Med J Aust; 1992 Nov; 157(9):599-601. PubMed ID: 1406420
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treating advanced ovarian cancer within the health maintenance organization: a Kaiser Permanente approach.
    Rarick M
    Semin Oncol; 1999 Feb; 26(1 Suppl 1):52-8. PubMed ID: 10071974
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer.
    Dalton HJ; Yu X; Hu L; Kapp DS; Benjamin I; Monk BJ; Chan JK
    Gynecol Oncol; 2012 Feb; 124(2):199-204. PubMed ID: 22055763
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The effect of selected gerontologic risk factors on the utilization of health services].
    Vozehová S
    Cesk Zdrav; 1987 Apr; 35(4):178-84. PubMed ID: 3594625
    [No Abstract]   [Full Text] [Related]  

  • 46. First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis.
    Neyt M; Vlayen J; Devriese S; Camberlin C
    PLoS One; 2018; 13(4):e0195134. PubMed ID: 29630612
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interpreting the economic literature in oncology.
    Grusenmeyer PA; Wong YN
    J Clin Oncol; 2007 Jan; 25(2):196-202. PubMed ID: 17210940
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Medicare in Quebec.
    Backman HA
    J Am Optom Assoc; 1976 Sep; 47(9):1205-10. PubMed ID: 798749
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-effectiveness of risk-reducing surgeries in preventing hereditary breast and ovarian cancer.
    Schrauder MG; Brunel-Geuder L; Häberle L; Wunderle M; Hoyer J; Reis A; Schulz-Wendtland R; Beckmann MW; Lux MP
    Breast; 2017 Apr; 32():186-191. PubMed ID: 28214786
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Trends in use of medical services by the elderly in British Columbia.
    Rosenberg JJ
    CMAJ; 1989 Dec; 141(12):1220-1. PubMed ID: 2512006
    [No Abstract]   [Full Text] [Related]  

  • 51. Budget impact model of a 5-grass sublingual immunotherapy tablet for the treatment of grass pollen-induced allergic rhinitis.
    Ivanova JI; Kelkar S; King S; Birnbaum HG; Hocker S; Phipps R; Lankow R
    J Med Econ; 2015; 18(11):909-18. PubMed ID: 26481690
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Influence of age structure of patients on the amount of expenditures for drugs].
    Zouplna K
    Cesk Zdrav; 1966 Sep; 14(9):498-500. PubMed ID: 5988859
    [No Abstract]   [Full Text] [Related]  

  • 53. Particulate air pollution in urban areas of Shanghai, China: health-based economic assessment.
    Kan H; Chen B
    Sci Total Environ; 2004 Apr; 322(1-3):71-9. PubMed ID: 15081739
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The economics of cochlear implant management in France: a multicentre analysis.
    Molinier L; Bocquet H; Bongard V; Fraysse B
    Eur J Health Econ; 2009 Jul; 10(3):347-55. PubMed ID: 19475439
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Improving NCCN guideline-adherent care for ovarian cancer: Value of an intervention.
    Dottino JA; Cliby WA; Myers ER; Bristow RE; Havrilesky LJ
    Gynecol Oncol; 2015 Sep; 138(3):694-9. PubMed ID: 26072441
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Problems in expressing performance in relation to costs in the health services].
    Stastná M
    Cesk Zdrav; 1990 Apr; 38(4):155-61. PubMed ID: 2350819
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Economic outcomes of breast cancer survivorship: CALGB study 79804.
    Hensley ML; Dowell J; Herndon JE; Winer E; Stark N; Weeks JC; Paskett E
    Breast Cancer Res Treat; 2005 May; 91(2):153-61. PubMed ID: 15868443
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Medical Care Costs of Breast Cancer in Privately Insured Women Aged 18-44 Years.
    Allaire BT; Ekwueme DU; Guy GP; Li C; Tangka FK; Trivers KF; Sabatino SA; Rodriguez JL; Trogdon JG
    Am J Prev Med; 2016 Feb; 50(2):270-7. PubMed ID: 26775906
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Compared medical costs of treating ovarian cancer patients with weekly paclitaxel, carboplatin (TC) chemotherapy].
    Nomura H; Nagai S; Shinohara T; Iwashita M; Yajima M; Takatoya S
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1091-4. PubMed ID: 17637546
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Economic evaluation of the costs and losses to society due to infections with hepatitis virus type B].
    Göpfertová D; Kreuzingerová S; Sejda J; Hazuka V; Drasnar M
    Cesk Epidemiol Mikrobiol Imunol; 1984 May; 33(3):142-8. PubMed ID: 6235930
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.